Expanded CD56 CD16+ NK Cells from Ovarian Cancer Patients Are Cytotoxic against Autologous Tumor in a Patient-Derived Xenograft
Murine Model
Poznanski, S.M. et al. Cancer Immunology Research. July 2018

Generation of Highly Cytotoxic Natural Killer Cells for Treatment of Acute Myelogenous Leukemia Using a Feeder-Free, Particle-Based Approach
Oyer, J.L. et al. Biology of Blood and Marrow Transplantation. 2015

Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
Denman, C.J. et al. Plos ONE. January 2012

Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment.
Oyer, J. L. et al. Cytotherapy. 2016

PD-L1 blockade enhances anti-tumor efficacy of NK cells.
Oyer, J.L., et al. Oncoimmunology. August 2018

PD-L1 blockade enhances anti-tumor efficacy of NK cells Supplemental Methods

Phase 1 clinical trial using mbIL21 ex vivo–expanded donor-derived NK cells after haploidentical transplantation.
Ciurea, S.O. et al. Blood. 19 October 2017

Phase 1 clinical trial using mbIL21 ex vivo–expanded donor-derived NK cells after haploidentical transplantation Supplemental Materials.

TGFβ Imprinting During Activation Promotes Natural Killer Cell Cytokine Hypersecretion.
Foltz, J.A., et al. Cancers. 05 November 2018

What Defines NK Cell Functional Fate: Phenotype or Metabolism?
Poznanski, S.M. Frontiers in Immunology. June 2019

ASH 2020 Annual Meeting
05 Dec2020 Oral presentation #68: Improved Outcomes for Patients Receiving High doses of mbIL-21 ex vivo Expanded NK Cells after Haploidentical Transplantation

ASH 2020 Annual Meeting
06Dec2020 Poster #2347: Haploidentical mbil-21 Ex Vivo Expanded NK Cells (FC21-NK) for Patients with Multiple Relapsed and Refractory Acute Myeloid Leukemia

SITC 2020 Annual Meeting
09Nov20 Poster #454: Oncolytic Parainfluenza Virus 5 Vector Enhances Natural Killer Cell Killing of Lung Tumor Cells in 2D and 3D spheroid cultures

September 2020 PEGS Boston
Leveraging PM21-NK Cells in IO Combinations for Treatment of Solid Tumors

August 2020 Innate Killer Summit
Leveraging NK Cells in IO Combinations for Treatment of Solid Tumors

2020 EBMT Virtual Annual Meeting
29Aug2020 e-Poster: Phase I Study of Adoptive Transfer of Haploidentical Expanded NK Cells

EHA 25th Congress
12Jun2020 Poster Presentation Abstract EP1487: Deep functional and phenotypic characterization* of expanded and cryopreserved NK cells establishes consistent product identity across GMP and clinical-scale manufacturing sites and FC21 and PM21 platforms as intended for clinical use

EHA 25th Congress
12Jun20 Poster Presentation Abstract #EP585: Clinical and Radiologic Resolution of Infections During Treatment with MBIL-21-expanded CD56Bright/CD16Bright NK Cells in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

EHA 25th Congress
12Jun20 Oral presentation Abstract #S284: Early-phase Clinical Trials of Adoptive Transfer of Hyperfunctional NK Cells Expanded Ex Vivo with IL-21 Demonstrate Functional, Phenotypic, and Haplotype-specific evidence of in vivo persistence

ASCO 2020 Virtual Annual Meeting
29May2020 Abstract TPS7562: A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-Shelf, Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia

ASCO 2020 Virtual Annual Meeting
29May20 Abstract e15018: Impact of CD38 knockout in NK cells on daratumumab-mediated cytotoxicity and cellular metabolism

ISCT 2020 Virtual Meeting
28May2020 Poster Presentation Abstract 228: Cytokine pre-activation enhances PM21-particle driven NK cell expansion

2020 ASGCT Virtual Annual Meeting
12May2020 Poster Presentation Abstract 765: NK Cell Expansion and Phenotype Shaping Using CD16-targeted CSTX002-Fc Feeder Cells

2020 ASGCT Virtual Annual Meeting
12May2020 Video: Bridging NK cell expansion methods towards a feeder-cell free scalable GMP production of hyperfunctional NK cells

2020 ASGCT Virtual Annual Meeting
12May2020 Poster Presentation Abstract 427: Bridging NK cell expansion methods towards a feeder-cell free scalable GMP production of hyperfunctional NK cells